CY1124140T1 - Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης - Google Patents
Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασηςInfo
- Publication number
- CY1124140T1 CY1124140T1 CY20211100256T CY211100256T CY1124140T1 CY 1124140 T1 CY1124140 T1 CY 1124140T1 CY 20211100256 T CY20211100256 T CY 20211100256T CY 211100256 T CY211100256 T CY 211100256T CY 1124140 T1 CY1124140 T1 CY 1124140T1
- Authority
- CY
- Cyprus
- Prior art keywords
- therapeutic treatment
- cell disorders
- hyperplastic cell
- entities
- telomerase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
- G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
Abstract
Παρέχονται στο παρόν μέθοδοι για τον προσδιορισμό οντοτήτων διαγνωσμένων με μία υπερπλαστική διαταραχή των κυττάρων που θα ωφεληθούν από την θεραπευτική αγωγή με ένωση αναστολέα τελομεράσης. Παρέχονται επίσης στο παρόν μέθοδοι για την θεραπευτική αντιμετώπιση σε τέτοιες οντότητες με ενώσεις αναστολέα τελομεράσης. Οι μέθοδοι περιέχουν τον προσδιορισμό οντοτήτων που θα ωφεληθούν από την εν λόγω θεραπευτική αγωγή που βασίζεται στο μέσο σχετικό μήκος των τελομερών σε καρκινικά κύτταρα από τις εν λόγω οντότητες.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261732263P | 2012-11-30 | 2012-11-30 | |
US201361780851P | 2013-03-13 | 2013-03-13 | |
US13/802,035 US9200327B2 (en) | 2012-11-30 | 2013-03-13 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
US201361798478P | 2013-03-15 | 2013-03-15 | |
US201361809228P | 2013-04-05 | 2013-04-05 | |
PCT/US2013/072302 WO2014085632A1 (en) | 2012-11-30 | 2013-11-27 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
EP13858528.6A EP2925889B1 (en) | 2012-11-30 | 2013-11-27 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124140T1 true CY1124140T1 (el) | 2022-05-27 |
Family
ID=50828470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100256T CY1124140T1 (el) | 2012-11-30 | 2021-03-23 | Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP3495495B1 (el) |
JP (2) | JP6359028B2 (el) |
KR (3) | KR102174763B1 (el) |
CN (2) | CN111494629A (el) |
AU (3) | AU2013352105B2 (el) |
BR (1) | BR112015012507B1 (el) |
CA (1) | CA2892445C (el) |
CY (1) | CY1124140T1 (el) |
DK (2) | DK2925889T3 (el) |
ES (3) | ES2865446T3 (el) |
HK (1) | HK1215874A1 (el) |
HR (2) | HRP20181991T1 (el) |
HU (1) | HUE054053T2 (el) |
IL (3) | IL282112B (el) |
LT (2) | LT3495495T (el) |
MX (1) | MX362094B (el) |
NZ (2) | NZ708654A (el) |
PL (2) | PL3495495T3 (el) |
PT (2) | PT3495495T (el) |
RS (1) | RS61513B1 (el) |
SG (1) | SG11201504209YA (el) |
SI (2) | SI3495495T1 (el) |
WO (1) | WO2014085632A1 (el) |
ZA (2) | ZA201900759B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3029154B1 (en) | 2008-10-17 | 2017-10-04 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
JPWO2018207952A1 (ja) * | 2017-05-12 | 2020-04-16 | 国立大学法人九州大学 | 発毛及び/又は育毛用組成物 |
KR20210038895A (ko) * | 2018-07-31 | 2021-04-08 | 제론 코포레이션 | 텔로머라제 억제제에 의한 치료로부터 이익일 것 같은 환자를 확인하는 방법 |
GB201818792D0 (en) * | 2018-11-19 | 2019-01-02 | Telonostix Ltd | Compounds for telomere length-related treatment of cancer |
EP3674418A1 (en) * | 2018-12-26 | 2020-07-01 | Life Length S.L. | Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases |
CN114306602B (zh) * | 2020-09-28 | 2024-06-11 | 中国科学院上海营养与健康研究所 | 靶向tert在调节皮肤及毛发色素中的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
JPH11276182A (ja) * | 1997-12-26 | 1999-10-12 | Chugai Pharmaceut Co Ltd | 逆転写酵素モチーフを有する新規遺伝子 |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
US7695904B2 (en) | 2002-01-31 | 2010-04-13 | University Of Utah Research Foundation | Reducing non-target nucleic acid dependent amplifications: amplifying repetitive nucleic acid sequences |
US20040234961A1 (en) * | 2002-04-22 | 2004-11-25 | Fordyce Colleen A. | Telomere length determination and applications |
EP1585974B1 (en) | 2003-01-24 | 2013-02-27 | University of Utah | Methods of predicting mortality risk by determining telomere length |
AU2004271215B2 (en) | 2003-09-09 | 2009-07-16 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
CN104997783A (zh) * | 2005-03-25 | 2015-10-28 | Alt解决方案公司 | 端粒酶阳性细胞中端粒长度的调节和癌症治疗 |
WO2006113470A2 (en) * | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
EP3029154B1 (en) * | 2008-10-17 | 2017-10-04 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
US9689028B2 (en) | 2008-12-22 | 2017-06-27 | University Of Utah Foundation | Monochrome multiplex quantitative PCR |
US20110207128A1 (en) | 2010-02-16 | 2011-08-25 | Cawthon Richard M | Methods and kits for determining biological age and longevity based on gene expression profiles |
WO2012135125A1 (en) * | 2011-03-28 | 2012-10-04 | Geron Corporation | Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr |
-
2013
- 2013-11-27 CA CA2892445A patent/CA2892445C/en active Active
- 2013-11-27 WO PCT/US2013/072302 patent/WO2014085632A1/en active Application Filing
- 2013-11-27 MX MX2015006538A patent/MX362094B/es active IP Right Grant
- 2013-11-27 ES ES18192236T patent/ES2865446T3/es active Active
- 2013-11-27 IL IL282112A patent/IL282112B/en unknown
- 2013-11-27 PT PT181922360T patent/PT3495495T/pt unknown
- 2013-11-27 CN CN201911349502.4A patent/CN111494629A/zh active Pending
- 2013-11-27 KR KR1020157017235A patent/KR102174763B1/ko active IP Right Grant
- 2013-11-27 PL PL18192236T patent/PL3495495T3/pl unknown
- 2013-11-27 HU HUE18192236A patent/HUE054053T2/hu unknown
- 2013-11-27 ES ES13858528T patent/ES2703914T3/es active Active
- 2013-11-27 KR KR1020217027659A patent/KR20210112394A/ko not_active Application Discontinuation
- 2013-11-27 LT LTEP18192236.0T patent/LT3495495T/lt unknown
- 2013-11-27 RS RS20210254A patent/RS61513B1/sr unknown
- 2013-11-27 PT PT13858528T patent/PT2925889T/pt unknown
- 2013-11-27 SI SI201331864T patent/SI3495495T1/sl unknown
- 2013-11-27 SI SI201331271T patent/SI2925889T1/sl unknown
- 2013-11-27 EP EP18192236.0A patent/EP3495495B1/en active Active
- 2013-11-27 NZ NZ708654A patent/NZ708654A/en unknown
- 2013-11-27 LT LTEP13858528.6T patent/LT2925889T/lt unknown
- 2013-11-27 ES ES20214086T patent/ES2972330T3/es active Active
- 2013-11-27 PL PL13858528T patent/PL2925889T3/pl unknown
- 2013-11-27 JP JP2015545446A patent/JP6359028B2/ja active Active
- 2013-11-27 SG SG11201504209YA patent/SG11201504209YA/en unknown
- 2013-11-27 DK DK13858528.6T patent/DK2925889T3/da active
- 2013-11-27 AU AU2013352105A patent/AU2013352105B2/en active Active
- 2013-11-27 KR KR1020207031441A patent/KR102348240B1/ko active IP Right Grant
- 2013-11-27 EP EP13858528.6A patent/EP2925889B1/en active Active
- 2013-11-27 CN CN201380070816.5A patent/CN104937110A/zh active Pending
- 2013-11-27 EP EP20214086.9A patent/EP3882355B1/en active Active
- 2013-11-27 DK DK18192236.0T patent/DK3495495T3/da active
- 2013-11-27 NZ NZ748624A patent/NZ748624A/en unknown
- 2013-11-27 BR BR112015012507-7A patent/BR112015012507B1/pt active IP Right Grant
-
2015
- 2015-05-27 IL IL239035A patent/IL239035B/en active IP Right Grant
-
2016
- 2016-04-01 HK HK16103783.7A patent/HK1215874A1/zh unknown
-
2018
- 2018-02-13 JP JP2018022923A patent/JP2018099127A/ja active Pending
- 2018-11-27 HR HRP20181991TT patent/HRP20181991T1/hr unknown
-
2019
- 2019-02-06 ZA ZA2019/00759A patent/ZA201900759B/en unknown
- 2019-11-13 IL IL270636A patent/IL270636B/en active IP Right Grant
- 2019-12-18 AU AU2019283840A patent/AU2019283840A1/en not_active Abandoned
-
2021
- 2021-02-26 ZA ZA2021/01317A patent/ZA202101317B/en unknown
- 2021-03-17 HR HRP20210451TT patent/HRP20210451T1/hr unknown
- 2021-03-23 CY CY20211100256T patent/CY1124140T1/el unknown
-
2022
- 2022-04-28 AU AU2022202808A patent/AU2022202808A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124140T1 (el) | Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης | |
CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
CY1124988T1 (el) | Μεθοδοι παρασκευης νεων αναστολεων idh1 | |
CY1123776T1 (el) | Μεθοδοι για την αντιμετωπιση καταστασεων που συνδεονται με την ενεργοποιηση συμπληρωματος εξαρτωμενου απο την μasp-2 | |
CY1124617T1 (el) | Ενωσεις βενζολιου υποκατεστημενες με αρυλιο ή ετεροαρυλιο | |
CY1121390T1 (el) | Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων | |
CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
CY1120374T1 (el) | Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια | |
CY1120581T1 (el) | Ενωσεις και μεθοδοι χρησης τους | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
CY1118933T1 (el) | Anti-cxcr1 συνθεσεις και μεθοδοι | |
UY34736A (es) | ?compuestos de indol e indazol que activan la ampk?. | |
TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
MY170983A (en) | Biomarker assays for detecting or measuring inhibition of tor kinase activity | |
TR201907240T4 (tr) | Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi. | |
CY1117654T1 (el) | Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης | |
UY34654A (es) | Inhibidores de la beta-secretasa | |
TR201909951T4 (tr) | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. | |
EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
MX2016007066A (es) | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
MX348655B (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. | |
MX2015010776A (es) | Metodos y composiciones para detectar y tratar mutantes de akt resistentes a farmacos. |